- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05345509
A Clinical Trial to Access Pharmacokinetic Profiles and Safety of IVL3003.
August 17, 2023 updated by: Inventage Lab., Inc.
A Phase 1, Randomized, Open-Label, Exploratory, Sequential, Pharmacokinetic Single Ascending Dose Study of IVL3003 Versus Multiple Doses of Aricept (Donepezil) Tablets in Healthy Subjects
A Clinical Trial to Assess Pharmacokinetic Profiles and Safety of IVL3003
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
A Phase 1, Randomized, Open-Label, Exploratory, Sequential, Pharmacokinetic Single Ascending Dose Study of IVL3003 Versus Multiple Doses of Aricept (Donepezil) Tablets in Healthy Subjects
Study Type
Interventional
Enrollment (Estimated)
42
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: SungJin Eum
- Phone Number: 5571 82-31-608-5135
- Email: sjeum@inventagelab.com
Study Locations
-
-
-
Melbourne, Australia
- Recruiting
- Nucleus Network
-
Contact:
- Chloe Hobbs
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Healthy male or female, ≥18 and ≤55 years of age, non-smokers or occasional smokers (defined as smoking less than 10 cigarettes or nicotine equivalent per week, and willing to abstain from smoking during confinement at the study site).
- Body mass index (BMI) ≥18.0 and ≤32.0 kg/m2 and body weight ≥55.0 kg for males and ≥50.0 kg for females.
- Male subjects who are sexually active with a same-sex partner must be willing to use a condom until study exit.
- Male and female subjects who practice abstinence from sexual intercourse as a usual and preferred lifestyle.
- Willing to abstain from use of non-steroidal anti-inflammatory drugs (NSAIDs) including ibuprofen, naproxen, aspirin, meloxicam, etc. from screening until study exit.
- Willing and able to provide written informed consent after the nature of the study has been explained and prior to the commencement of any protocol specific study procedures.
Exclusion Criteria:
- Any clinically significant abnormal finding at physical examination at screening.
- Clinically significant abnormal laboratory test results or positive serology test results for human immunodeficiency virus (HIV), hepatitis B or hepatitis C virus at screening.
- Positive pregnancy test at screening or Day -1 or lactating female subject.
- Positive drug or alcohol screen at screening or Day -1.
- Any history of malignancy or neoplastic disease.
- History of significant allergic reactions (e.g., drug reaction, anaphylactic reaction, hypersensitivity, angioedema) to donepezil, piperidine derivatives, dimenhydrinate or derivatives, benzatropine or derivatives, or other related drugs, or to any excipient present in the formulation for any study drug.
- Presence of hereditary disorders including galactose intolerance, lactase deficiency, and glucose-galactose malabsorption (for Part B only).
- Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin >1.5x the upper limit of normal (ULN) at screening or Day -1.
- Estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m2 as calculated by the 2021 Chronic Kidney Disease-Epidemiology (CKD-EPI) equation at screening or Day -1.
- Clinically significant ECG abnormalities (QTc >450 ms or PR interval >220 ms) or vital sign abnormalities (systolic blood pressure <90 or >140 mmHg, diastolic blood pressure <40 or >90 mmHg, or heart rate <50 or >100 bpm) at screening or Day 1.
- History of significant bradycardia or atrioventricular (AV) block.
- History of significant asthma (except for fully resolved childhood asthma) or chronic obstructive pulmonary disease (COPD).
- History of alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to screening that exceeds 14 units of alcohol per week (1 unit = 375 mL of beer 3.5%, 100 mL of wine 13.5%, or 30 mL of spirit 40%).
- History of drug abuse within 1 year prior to screening or recreational use of soft drugs (such as marijuana) or hard drugs (such as cocaine, phencyclidine [PCP], crack, opioid derivatives including heroin, and amphetamine derivatives) within 1 month, or use of codeine within 3 months prior to screening.
- Donation of plasma within 7 days prior to dosing or donation or loss of 500 mL or more of whole blood within 30 days prior to dosing.
- Consumption of high levels of caffeine (equivalent to 3 regular cups of coffee or 2 energy drinks, per day).
- Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Aricept Tablet
Aricept Tablet, QD, PO
|
Donepezil Tablet once daily P.O
|
Experimental: IVL3003 (A mg)
SC, Single Dose
|
Donepezil Long-Acting Injection, once S.C Injection
|
Experimental: IVL3003 (B mg)
SC, Single Dose
|
Donepezil Long-Acting Injection, once S.C Injection
|
Experimental: IVL3003 (C mg)
SC, Single Dose
|
Donepezil Long-Acting Injection, once S.C Injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUClast of IVL3003
Time Frame: Pre-dose, up to 1month
|
Area under the concentration-time curve from time zero to last
|
Pre-dose, up to 1month
|
AUCinf of IVL3003
Time Frame: Pre-dose, up to 1month
|
Area under the concentration-time curve from time zero to infinity
|
Pre-dose, up to 1month
|
AUClast of Aricept
Time Frame: Pre-dose, up to 1month
|
Area under the concentration-time curve from time zero to last
|
Pre-dose, up to 1month
|
AUCinf of Aricept
Time Frame: Pre-dose, up to 1month
|
Area under the concentration-time curve from time zero to infinity
|
Pre-dose, up to 1month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2023
Primary Completion (Estimated)
March 31, 2024
Study Completion (Estimated)
March 31, 2024
Study Registration Dates
First Submitted
April 19, 2022
First Submitted That Met QC Criteria
April 25, 2022
First Posted (Actual)
April 26, 2022
Study Record Updates
Last Update Posted (Actual)
August 22, 2023
Last Update Submitted That Met QC Criteria
August 17, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurocognitive Disorders
- Neurodegenerative Diseases
- Dementia
- Tauopathies
- Alzheimer Disease
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Cholinergic Agents
- Enzyme Inhibitors
- Nootropic Agents
- Cholinesterase Inhibitors
- Donepezil
Other Study ID Numbers
- IVL3003-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on Aricept Tablet
-
Dong-A ST Co., Ltd.Active, not recruitingHealthyKorea, Republic of
-
Dong-A ST Co., Ltd.Completed
-
Corium, Inc.CompletedAlzheimer DiseaseUnited States
-
Eisai Inc.PfizerWithdrawnSevere Alzheimer's DiseaseUnited States
-
Eisai Inc.Eisai Co., Ltd.CompletedVascular DementiaPhilippines
-
Dr. Reddy's Laboratories LimitedCompleted
-
AstraZenecaCompletedAlzheimer's DiseasePeru, Poland, Canada, South Africa
-
Dr. Reddy's Laboratories LimitedCompleted
-
PfizerCompletedDementia | Alzheimer's DiseaseUnited States
-
Eisai Inc.Eisai LimitedCompleted